The global growth hormone secretagogue receptor type 1 market is expected to grow at a CAGR of XX% during the forecast period. The growth is attributed to the increasing prevalence of obesity and diabetes, which are major risk factors for cancer.
The global growth hormone secretagogue receptor type 1 market is segmented on the basis of type (AZ531, EX400, H01, OX103), application (radiation toxicity, chemotherapy effects) and region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa). North America accounted for the largest share in 2018 owing to its high prevalence of obesity and diabetes. The region also has a large number of cancer patients undergoing chemotherapy treatment.
Some Of The Growth Factors Of This Market:
- Growth hormone secretagogue receptor type 1 is a protein that in humans is encoded by the GHSR1 gene.
- The growth hormone secretagogue receptor type 1 is a G-protein coupled receptor that binds to ghrelin and other growth hormones, and stimulates the release of growth hormone from the pituitary gland.
- Ghrelin, also known as "the hunger hormone," is an appetite stimulant produced by cells in the stomach lining when it's empty or not producing enough acid to break down food properly.
- Ghrelin levels rise before meals and fall after eating, which may be one reason why people who are hungry eat more than those who are full or satisfied with their meal size; ghrelin levels also rise during periods of fasting (e.g., sleep).
- Ghrelin has been shown to increase fat breakdown in adipose tissue, suppress synthesis of glucose from amino acids in liver cells, stimulate appetite and food intake, inhibit insulin secretion from pancreatic beta cells.
Industry Growth Insights published a new data on “Growth Hormone Secretagogue Receptor Type 1 Market”. The research report is titled “Growth Hormone Secretagogue Receptor Type 1 Market research by Types (AZP-531, EXT-400, HM-01, OXE-103, Others), By Applications (Radiation Toxicity, Chemotherapy Effects, Alconol Addiction, Others), By Players/Companies Aeterna Zentaris Inc, Alize Pharma SAS, Allergan Plc, AstraZeneca Plc, Daiichi Sankyo Co Ltd, Oxeia Biopharmaceuticals Inc, Pfizer Inc, RaQualia Pharma Inc, Zeria Pharmaceutical Co Ltd”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Growth Hormone Secretagogue Receptor Type 1 Market Research Report
By Type
AZP-531, EXT-400, HM-01, OXE-103, Others
By Application
Radiation Toxicity, Chemotherapy Effects, Alconol Addiction, Others
By Companies
Aeterna Zentaris Inc, Alize Pharma SAS, Allergan Plc, AstraZeneca Plc, Daiichi Sankyo Co Ltd, Oxeia Biopharmaceuticals Inc, Pfizer Inc, RaQualia Pharma Inc, Zeria Pharmaceutical Co Ltd
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
247
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Growth Hormone Secretagogue Receptor Type 1 Market Report Segments:
The global Growth Hormone Secretagogue Receptor Type 1 market is segmented on the basis of:
Types
AZP-531, EXT-400, HM-01, OXE-103, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Radiation Toxicity, Chemotherapy Effects, Alconol Addiction, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Aeterna Zentaris Inc
- Alize Pharma SAS
- Allergan Plc
- AstraZeneca Plc
- Daiichi Sankyo Co Ltd
- Oxeia Biopharmaceuticals Inc
- Pfizer Inc
- RaQualia Pharma Inc
- Zeria Pharmaceutical Co Ltd
Highlights of The Growth Hormone Secretagogue Receptor Type 1 Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- AZP-531
- EXT-400
- HM-01
- OXE-103
- Others
- By Application:
- Radiation Toxicity
- Chemotherapy Effects
- Alconol Addiction
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Growth Hormone Secretagogue Receptor Type 1 Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Growth hormone secretagogue receptor type 1 (GHS-R1) is a protein that binds to growth hormone secretagogues, such as ghrelin, and stimulates their release from the cells. This action leads to increased growth and development in the body.
Some of the major companies in the growth hormone secretagogue receptor type 1 market are Aeterna Zentaris Inc, Alize Pharma SAS, Allergan Plc, AstraZeneca Plc, Daiichi Sankyo Co Ltd, Oxeia Biopharmaceuticals Inc, Pfizer Inc, RaQualia Pharma Inc, Zeria Pharmaceutical Co Ltd.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Growth Hormone Secretagogue Receptor Type 1 Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Growth Hormone Secretagogue Receptor Type 1 Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Growth Hormone Secretagogue Receptor Type 1 Market - Supply Chain
4.5. Global Growth Hormone Secretagogue Receptor Type 1 Market Forecast
4.5.1. Growth Hormone Secretagogue Receptor Type 1 Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Growth Hormone Secretagogue Receptor Type 1 Market Size (000 Units) and Y-o-Y Growth
4.5.3. Growth Hormone Secretagogue Receptor Type 1 Market Absolute $ Opportunity
5. Global Growth Hormone Secretagogue Receptor Type 1 Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Growth Hormone Secretagogue Receptor Type 1 Market Size and Volume Forecast by Type
5.3.1. AZP-531
5.3.2. EXT-400
5.3.3. HM-01
5.3.4. OXE-103
5.3.5. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Growth Hormone Secretagogue Receptor Type 1 Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Growth Hormone Secretagogue Receptor Type 1 Market Size and Volume Forecast by Application
6.3.1. Radiation Toxicity
6.3.2. Chemotherapy Effects
6.3.3. Alconol Addiction
6.3.4. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Growth Hormone Secretagogue Receptor Type 1 Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Growth Hormone Secretagogue Receptor Type 1 Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Growth Hormone Secretagogue Receptor Type 1 Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Growth Hormone Secretagogue Receptor Type 1 Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Growth Hormone Secretagogue Receptor Type 1 Demand Share Forecast, 2019-2026
9. North America Growth Hormone Secretagogue Receptor Type 1 Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Growth Hormone Secretagogue Receptor Type 1 Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Growth Hormone Secretagogue Receptor Type 1 Market Size and Volume Forecast by Application
9.4.1. Radiation Toxicity
9.4.2. Chemotherapy Effects
9.4.3. Alconol Addiction
9.4.4. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Growth Hormone Secretagogue Receptor Type 1 Market Size and Volume Forecast by Type
9.7.1. AZP-531
9.7.2. EXT-400
9.7.3. HM-01
9.7.4. OXE-103
9.7.5. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Growth Hormone Secretagogue Receptor Type 1 Demand Share Forecast, 2019-2026
10. Latin America Growth Hormone Secretagogue Receptor Type 1 Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Growth Hormone Secretagogue Receptor Type 1 Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Growth Hormone Secretagogue Receptor Type 1 Market Size and Volume Forecast by Application
10.4.1. Radiation Toxicity
10.4.2. Chemotherapy Effects
10.4.3. Alconol Addiction
10.4.4. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Growth Hormone Secretagogue Receptor Type 1 Market Size and Volume Forecast by Type
10.7.1. AZP-531
10.7.2. EXT-400
10.7.3. HM-01
10.7.4. OXE-103
10.7.5. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Growth Hormone Secretagogue Receptor Type 1 Demand Share Forecast, 2019-2026
11. Europe Growth Hormone Secretagogue Receptor Type 1 Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Growth Hormone Secretagogue Receptor Type 1 Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Growth Hormone Secretagogue Receptor Type 1 Market Size and Volume Forecast by Application
11.4.1. Radiation Toxicity
11.4.2. Chemotherapy Effects
11.4.3. Alconol Addiction
11.4.4. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Growth Hormone Secretagogue Receptor Type 1 Market Size and Volume Forecast by Type
11.7.1. AZP-531
11.7.2. EXT-400
11.7.3. HM-01
11.7.4. OXE-103
11.7.5. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Growth Hormone Secretagogue Receptor Type 1 Demand Share, 2019-2026
12. Asia Pacific Growth Hormone Secretagogue Receptor Type 1 Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Growth Hormone Secretagogue Receptor Type 1 Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Growth Hormone Secretagogue Receptor Type 1 Market Size and Volume Forecast by Application
12.4.1. Radiation Toxicity
12.4.2. Chemotherapy Effects
12.4.3. Alconol Addiction
12.4.4. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Growth Hormone Secretagogue Receptor Type 1 Market Size and Volume Forecast by Type
12.7.1. AZP-531
12.7.2. EXT-400
12.7.3. HM-01
12.7.4. OXE-103
12.7.5. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Growth Hormone Secretagogue Receptor Type 1 Demand Share, 2019-2026
13. Middle East & Africa Growth Hormone Secretagogue Receptor Type 1 Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Growth Hormone Secretagogue Receptor Type 1 Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Growth Hormone Secretagogue Receptor Type 1 Market Size and Volume Forecast by Application
13.4.1. Radiation Toxicity
13.4.2. Chemotherapy Effects
13.4.3. Alconol Addiction
13.4.4. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Growth Hormone Secretagogue Receptor Type 1 Market Size and Volume Forecast by Type
13.7.1. AZP-531
13.7.2. EXT-400
13.7.3. HM-01
13.7.4. OXE-103
13.7.5. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Growth Hormone Secretagogue Receptor Type 1 Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Growth Hormone Secretagogue Receptor Type 1 Market: Market Share Analysis
14.2. Growth Hormone Secretagogue Receptor Type 1 Distributors and Customers
14.3. Growth Hormone Secretagogue Receptor Type 1 Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Aeterna Zentaris Inc
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Alize Pharma SAS
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Allergan Plc
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. AstraZeneca Plc
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Daiichi Sankyo Co Ltd
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Oxeia Biopharmaceuticals Inc
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Pfizer Inc
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. RaQualia Pharma Inc
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Zeria Pharmaceutical Co Ltd
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
